“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Sequana Medical
Based in Belgium, Sequana Medical develops products to treat diuretic-resistant fluid overload, a frequent complication of liver disease and heart failure (HF). Its proprietary alfapump and Direct Sodium Removal (DSR) approaches aim to provide significant clinical and quality-of-life benefits.
Sequana Medical — 2 videos in collection
Sequana Medical is a Belgian commercial-stage medical device company that uses its proprietary alfapump and Direct Sodium Removal (DSR) technologies to develop innovative treatments for diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure. The alfapump is CE marked for refractory ascites and is in a pivotal North American study covering this indication.
In this interview, chief executive officer Ian Crosbie describes the commercial opportunities for the alfapump and DSR platforms in areas of unmet medical need, highlights the company’s recent activities and clinical results and provides an overview of key upcoming catalysts and milestones.
Get access to the very latest content matched to your personal investment style.
